市場調查報告書
商品編碼
1335937
全球細胞分離市場規模、佔有率和行業趨勢分析報告:按產品類型、最終用途、細胞類型(動物細胞、人類細胞)、技術、用途以及按地區分類的展望和預測,2023-2030年Global Cell Separation Market Size, Share & Industry Trends Analysis Report By Product Type, By End-Use, By Cells Type (Animal Cell, and Human Cell), By Technique, By Application, By Regional Outlook and Forecast, 2023 - 2030 |
2030年,細胞分離市場規模預計將達到175億美元,預測期內市場年複合成長率率為10.2%。
根據 KBV Cardinal 矩陣中發布的分析,Thermo Fisher Scientific, Inc. 和 Danaher Corporation 是市場推動者。 2022 年10 月,賽默飛世爾科技(Thermo Fisher Scientific) 宣布推出Gibco CTS DynaCellect 磁力分離系統,這是一種先進的細胞分離、細胞活化、細胞去除和Dynabeads 磁珠去除裝置,使細胞療法開發人員能夠改進製程和臨床。從開發轉向商業化生產。 Merck KGaA、Becton、Dickinson and Company 和 Agilent Technologies, Inc. 等公司是該市場的主要創新者。
COVID-19 的影響
這場流行病擾亂了全球供應鏈,影響了細胞分離過程中使用的研究消耗品、試劑和消耗品的製造和交付。關鍵材料的延誤或短缺可能會阻礙科學和醫學應用。封鎖、社交距離政策和有限的能力擾亂了研究機構和實驗室的正常運作。許多研究人員發現很難進入實驗室並進行實驗,這可能影響了使用細胞分離技術的研究。生產尖端細胞藥物的未來和市場持續的技術創新預計將支持市場成長。
市場成長要素
慢性病增加
由於久坐的生活方式、全球人口高齡化、菸草和酒精使用增加以及其他原因,糖尿病、肥胖、關節炎、心臟病和癌症等慢性疾病呈上升趨勢。倫敦帝國學院估計,2020年,慢性病年度導致約4,100萬人死亡,佔全球死亡人數的十分之七。其中近 1700 萬人過早死亡,平均死亡人數比預期的要年輕。因此,隨著慢性疾病負擔的增加,對細胞療法的需求也隨之增加。由於慢性病患病上升,預計該市場在預測期內將大幅成長。
高齡化增加了對臨床試驗和研究的需求
老年人癌症和神經系統疾病等慢性疾病的患病高於年輕人。此外,老年人口的成長速度快於年輕人口。隨著 65 歲及以上人口的增加,阿茲海默症、失智症、癌症和免疫失調等疾病預計將變得更加常見。據聯合國稱,到2050年,60歲及以上的人口數量將增加一倍,到2100年將增加兩倍,從2017年的9.62億增加到2050年的21億和2100年的31億。預計會的。因此,隨著人口高齡化的增加,對細胞分離的需求可能會增加。
市場抑制因素
細胞療法開發的挑戰
市場在細胞療法的開發中面臨重大障礙,需要分離和操作特定的治療細胞類型。由於不同細胞類型的性質和作用不同,因此很難分離和精製特定的細胞群。結果,可能會產生不同的細胞群,可能會降低治療的有效性。為了用於治療,分離的細胞必須具有功能和活力。此外,細胞分離技術所需的設備和設備成本相當高,在資金支援較少的設施中減少了其使用。總的來說,細胞療法開拓的這些障礙是一個重大的市場挑戰。因此,未來年度市場成長可能會放緩。
產品類型展望
依產品類型分類,市場分為消耗品和電器。到 2022 年,家電領域將在市場中佔據重要的收入佔有率。公司正在著手開發永續技術,以獲得市場競爭優勢,從而支持該領域的成長。例如,Element Biosciences 於 2022 年 3 月披露了有關其未來 Aviti DNA 序列的資訊。該產品預計將成為一種新的桌上型儀器,因為製造商聲稱它可以減少試劑消費量並顯著降低成本。
消耗品類型展望
消耗品市場分為試劑、試劑盒、培養基/血清、珠子和拋棄式用品。 2022年,試劑、試劑盒、培養基和血清將佔市場最大的銷售佔有率。用於細胞分離的試劑和試劑盒是高度專業化的,針對特定的細胞類型和標記。這種特異性提高了分離群體的品質並減少了其他細胞類型的污染。生產細胞分離培養基、血清、試劑盒和試劑的公司通常擁有該行業的專業知識。他們的專業知識和幫助將幫助研究人員解決問題並改進細胞分離技術。
設備類型展望
設備分為離心機、流式細胞儀、過濾系統、磁激活細胞分離系統。 2022年,離心機領域佔據最大的收入佔有率。最重要的步驟之一是離心。最流行的細胞分離技術是差速離心和密度梯度離心。許多科學和生化研究需要能夠分離細胞器(例如粒線體、細胞核)和細胞大分子(例如蛋白質、RNA、DNA)。離心使這成為可能。
最終用途展望
根據最終用途,市場分為實驗室/研究機構、醫院/診斷實驗室、細胞庫和生物技術/生物製藥公司。 2022 年,研究實驗室部門在市場中佔據重要的收入佔有率。這可能是由於研究機構加強了研發力度,開發新型腫瘤學和神經科學療法。世界各地研究設施和實驗室的擴建預計也將成為該領域成長的要素。
細胞類型展望
根據細胞類型,市場分為人類細胞和動物細胞。到 2022 年,人體細胞領域預計將在市場中佔據顯著的收入佔有率。推動最高市場佔有率的主要要素之一是對人類和癌症研究的日益關注,以及分離的人類細胞在生物製藥開發、臨床試驗和研究中的廣泛用途,原因是它已經開始發揮作用。此外,已開發國家個人化醫療的優惠報銷政策正在增加對人體細胞分離的需求。
技術展望
按技術分類,市場分為離心、表面標誌物和過濾。在 2022 年的市場中,表面標誌物部門獲得了可觀的收入佔有率。表面標誌物分離是根據細胞和組織的表面標誌物來分離細胞和組織。特定細胞或組織類型特有的分子有蛋白質、碳水化合物、脂質等。這個過程使科學家能夠從混合物中區分和分離特定的細胞或組織類型。
應用前景
依用途,市場分為生物分子分離、癌症研究、幹細胞研究、組織再生、體外診斷和治療藥物。 2022 年,癌症研究領域在市場中佔據了重要的收入佔有率。公司和學術機構對細胞研究的投資增加是該細分市場擴張的主要要素。由於全球癌症罹患率不斷上升,許多公共和私人組織正在大力投資癌症研究,推動了對創新細胞分離解決方案的需求。
區域展望
從區域來看,我們對北美、歐洲、亞太地區和拉丁美洲地區的市場進行了分析。 2022年,北美地區以最高的收入佔有率引領市場。這是由於美國成熟的製藥和生技產業。該國對於最尖端科技的接受率也很高。全部區域研究型大學在細胞治療方面進行的廣泛研究活動也產生了對細胞分離技術的高需求。
The Global Cell Separation Market size is expected to reach $17.5 billion by 2030, rising at a market growth of 10.2% CAGR during the forecast period.
Several stem cell & gene therapy research projects are ongoing in Japan, China, and South Korea. Hence, the Asia Pacific region captured $2,143.9 million revenue in 2022. Cell separation is a crucial stage in the development of cell-based therapies. Government agencies from all over the world have provided funding for cell-based research because it is essential for many applications. A rise in healthcare expenditure and an increase in the market penetration of major global participants in crucial Asia Pacific countries drives the growth of the market.
The major strategies followed by the market participants are Product Launches as the key developmental strategy to keep pace with the changing demands of end users. For instance, In March, 2023, Agilent Technologies Inc. enhanced capabilities of Cell Analysis Workflow Automation by integrating xCELLigence RTCA HT, to enables researchers to analyze up to eight 384-well E-Plates, enhancing throughput and decreasing sample sizes. Additionally, In May, 2023, Akadeum Life Sciences introduced Human T Cell Activation & Expansion Positive Selection Kit, Microbubble Leukopak Human T Cell Isolation Kit, and Microbubble Leukopak Human PBMC Isolation Kit, the series of products for cell therapy research and development.
Based on the Analysis presented in the KBV Cardinal matrix; Thermo Fisher Scientific, Inc. and Danaher Corporation are the forerunners in the Market. In October, 2022, Thermo Fisher Scientific Inc. introduced Gibco CTS DynaCellect Magnetic Separation System, the advanced cell isolation, cell activation, cell depletion, and Dynabeads magnetic beads removal instrument, to help cell therapy developers simply move from process and clinical development to commercial manufacturing. Companies such as Merck KGaA, Becton, Dickinson and Company and Agilent Technologies, Inc. are some of the key innovators in the Market.
COVID-19 Impact
The pandemic caused global supply chains to become disrupted, which had an impact on the manufacturing and delivery of lab supplies, reagents, and consumables used in cell separation processes. Delays or shortages of crucial materials may have hampered applications in science and medicine. Lockdowns, social segregation policies, and capacity limitations hampered regular operations in research institutions and laboratories. Numerous researchers had difficulties getting to their labs or running experiments, which may have impacted their work utilizing cell separation technology. Future in creating cutting-edge cell-based medicines and ongoing innovation in the market are estimated to support the market's growth.
Market Growth Factors
Increasing prevalence of chronic diseases
Chronic diseases like diabetes, obesity, arthritis, heart conditions, and cancer are on the rise due to increased sedentary lifestyles, aging of the world population, increased cigarette & alcohol use, and other causes. The Imperial College London in 2020 estimated that the chronic illnesses will account for about 41 million deaths yearly or seven out of ten fatalities globally. Nearly 17 million deaths are considered premature, with the average person passing away younger than anticipated. Owing to this, as the burden of chronic diseases increases, so does the need for cellular therapies. As a result of the rising prevalence of chronic diseases, the market is estimated to grow significantly during the projection period.
The aging population is driving up demand for clinical trials & research
The prevalence of chronic diseases, including cancer and neurological problems, is higher among the elderly than the younger population. In addition, the elderly population is expanding swiftly compared to younger people. As the population over 65 grows, it is expected that diseases like Alzheimer's, dementia, cancer, and immunological disorders will become increasingly common. According to the United Nations, the population of people over 60 is predicted to double by 2050 and triple by 2100, going from 962 million in 2017 to 2.1 billion in 2050 and 3.1 billion in 2100. As a result, the need for cell separation will grow as result of the rising aging population.
Market Restraining Factors
Challenges in developing cell-therapies
The market faces a significant obstacle in developing cell therapies, necessitating isolation and manipulation of specific therapeutic cell types. It is challenging to separate and purify particular cell populations because different cell types have varied properties and roles. A diverse population of cells may be produced as a result, which may lessen the efficacy of the therapy. To be employed in therapies, isolated cells must be functioning and viable. Additionally, the cost of equipment and devices required for cell separation techniques is considerably high, decreasing their use in facilities with less financial aid. These barriers to the development of cell treatments represent significant market challenges overall. In light of this, the market may witness slow growth in the upcoming years.
Product Type Outlook
By product type, the market is classified into consumables and instruments. The instruments segment covered a considerable revenue share in the market in 2022. Companies have started developing sustainable technologies to acquire a competitive edge in the market which is supporting segment's growth. For instance, Element Biosciences revealed information about future Aviti DNA sequences in March 2022. The product is anticipated to be a new benchtop instrument since the manufacturer claims it can reduce reagent consumption and cut costs significantly.
Consumables Type Outlook
Under consumables, the market is categorized into reagents, kits, media, & sera, beads, and disposables. In 2022, reagents, kits, media, & sera witnessed the largest revenue share in the market. Targeting certain cell types or markers, reagents and kits made for cell separation are very specialized. The quality of the isolated population is improved and contamination from other cell types is reduced thanks to this specificity, which also ensures that the required cells are accurately isolated. Companies that create medium, sera, kits, and reagents for cell separation often have specific knowledge in the industry. Their expertise and assistance can help researchers troubleshoot problems and improve their cell separation techniques.
Instruments Type Outlook
Under instruments, the market is segmented into centrifuges, flow cytometers, filtration systems, and magnetic-activated cell separator systems. In 2022 the centrifuges segment dominated the with maximum revenue share. One of the most significant procedures is centrifugation. The most popular cell separation techniques are differential centrifugation and density gradient centrifugation. Many scientific and biochemical research require the ability to isolate subcellular components, such as organelles (such as mitochondria, nuclei), and cellular macromolecules (such as proteins, RNA, and DNA). This is made possible by centrifugation.
End-Use Outlook
Based on end-use, the market is segmented into research laboratories & institutes, hospitals & diagnostic laboratories, cell banks, and biotechnology & biopharmaceutical companies. In 2022, the research laboratories and institutes segment covered a considerable revenue share in market. This can be ascribed to the growing R&D efforts by research institutions to develop novel oncology and neuroscience therapies. The expansion of research facilities and labs around the world is also projected to be a critical factor in the segment's growth.
Cells Type Outlook
Based on cells type, the market is divided into human cell and animal cell. In 2022, the human cell segment projected a prominent revenue share in the market. One of the main drivers driving its highest share is the growing emphasis on human and cancer research and the various uses of isolated human cells in biopharmaceutical development, clinical trials, and research. In addition, favorable reimbursement policies for personalized medicine in developed nations increase the demand for human cell isolation.
Technique Outlook
On the basis of technique, the market is bifurcated into centrifugation, surface marker, and filtration. The surface maker segment acquired a substantial revenue share in the market in 2022. Surface markers separation is dividing cells or tissues according to their surface markers. The molecules unique to a particular cell or tissue type can be proteins, carbohydrates, lipids, or others. This procedure allows scientists to distinguish and isolate specific cell or tissue types from a mixture.
Application Outlook
By application, the market is fragmented into biomolecule isolation, cancer research, stem cell research, tissue regeneration, in vitro diagnostics, and therapeutics. The cancer research segment acquired a substantial revenue share in the market in 2022. Growing investment in cell-based research by businesses and academic institutions is a major factor behind the segment's expansion. Due to the rising global incidence of cancer, numerous public-private organizations are investing significantly in cancer research, thereby driving the demand for innovative cell separation solutions.
Regional Outlook
Region wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. This can be attributed to the fact that the pharmaceutical and biotech industries are well-established in the United States. Also, the country has a high acceptance rate for cutting-edge technologies. Substantial demand for cell separation technologies has also been generated by the extensive research activities conducted by research universities in cell treatments across the region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Merck KGaA, Danaher Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Corning Incorporated, Terumo Corporation, STEMCELL Technologies, Inc. and Akadeum Life Sciences, Inc.
Recent Strategies Deployed in Cell Separation Market
Partnerships, Collaborations and Agreements:
Feb-2023: Thermo Fisher Scientific came into a collaboration with Celltrio, a manufacturer of cell culturing automation and biobanking solutions. Through this collaboration, both companies aim to bring automated cell culture systems to biotherapeutic customers. Moreover, the collaboration would combine the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to fulfil the unmet market requirement for high-throughput automated cell line maintenance and culturing.
Apr-2022: STEMCELL Technologies Canada Inc. collaborated with Applied Cells, Inc., a company engaged in creating solutions to execute the workflow of cell separation and enrichment products. Under this collaboration, both companies would aim to offer a newly advanced cell separation solution that combines STEMCELL's EasySep™ immunomagnetic cell separation kits with Applied Cells' MARS platform.
Jun-2021: Bio-Rad Laboratories signed an agreement with Seegene, a leading biotechnology business. Following this agreement, Bio-Rad aimed to leverage the capabilities of Seegene to accelerate its penetration within the United States market by receiving FDA approvals for its clinical assays.
Mar-2021: Bio-Rad Laboratories, Inc. expanded its partnership with Roche, a Sweden-based healthcare company. Through this partnership, Bio-Rad Laboratories would offer InteliQ products, a range of barcoded, load-and-go quality control tubes which delivers efficiencies in workflow, moreover to Bio-Rad's Unity QC data management solutions, that help enhance a laboratory's analytical performance.
Product Launches and Product Expansions:
May-2023: Becton, Dickinson, and Company released BD FACSDiscover S8 Cell Sorter, a new-to-world cell sorting instrument consisting of BD CellView Image Technology and BD SpectralFX Technology. The two latest technology allows researchers to uncover more details about cells that were absent previously.
May-2023: Akadeum Life Sciences introduced Human T Cell Activation & Expansion Positive Selection Kit, Microbubble Leukopak Human T Cell Isolation Kit, and Microbubble Leukopak Human PBMC Isolation Kit, the series of products for cell therapy research and development. This launched product broadens Akadeum's lineup of Buoyancy-Activated Cell Sorting Microbubble buoyancy-based cell isolation kits, allowing the direct isolation of T cells and peripheral blood mononuclear cells from leukapheresis material.
Mar-2023: Agilent Technologies Inc. enhances capabilities of Cell Analysis Workflow Automation by integrating xCELLigence RTCA HT, a real-time cell analysis high throughput platform, with the BioTek BioSpa 8 Automated Incubator. The Combination offers a non-invasive, label-free kinetic readout of cell proliferation and cytotoxicity that enables researchers to analyse up to eight 384-well E-Plates, enhancing throughput and decreasing sample sizes.
Oct-2022: Thermo Fisher Scientific Inc. introduced Gibco CTS DynaCellect Magnetic Separation System, the advanced cell isolation, cell activation, cell depletion, and Dynabeads magnetic beads removal instrument. The launch aims to help cell therapy developers simply move from process and clinical development to commercial manufacturing.
Sep-2022: Akadeum Life Sciences launched the Microbubble Leukopak Human T Cell Isolation Kit. The newly launched kit was developed to provide scientists with an important solution to biological and workflow challenges in the lab.
Sep-2022: Terumo Blood and Cell Technologies rolled out the Quantum Flex Cell Expansion System, the system enabling developers to complete early process development on the same platform they would use for manufacturing. This launch aims to progress allogenic and autologous applications and also viral vector and exosome production in various bioreactor sizes, allowing for process efficiencies in batch size.
May-2022: Akadeum Life Sciences, Inc. released a human B cell isolation product, the expansion of its cell separation product offerings. The launched product solves shortcomings of current standard methods consisting of volume limitations and low throughput as a result of cumbersome and expensive processes.
Mar-2022: Thermo Fisher Scientific announced the launch of The Gibco CTS Xenon Electroporation System, the latest large-volume electroporation system that enables cell therapy developers to rapidly move from clinical development to commercial manufacturing. Additionally, The product aligns with a closed, highly flexible design to support gene modifications without traditional viral vectors.
Acquisitions and Mergers:
Feb-2022: BD took over Cytognos, a Biotech company. Through this acquisition, the company aimed to expedite the strategy of BD to help in the management of chronic diseases by expanding its offerings, which include immune assessment tests, blood cancer diagnostics, and informatics to address the demands of clinicians, patients, and care providers.
Jun-2021: Danaher took over Precision NanoSystems (PNI), a company that develops technologies and solutions for genetic medicines. Under this acquisition, the Vancouver, Canada-based company would join Danaher's life sciences platform, complementing the portfolios of both Cytiva and Pall.
Jun-2021: Danaher completed the acquisition of Aldevron, a US-based biotech business. With this acquisition, Danaher would expand its abilities into the crucial field of genomic medicine and help consumers and their essential task to obtain more life-saving treatments and vaccines to market quickly.
Feb-2021: Thermo Fisher Scientific took over Cell Sorting Technology from Propel Labs, a biotechnology instrumentation company. Through this acquisition, Thermo Fisher strengthens its cell therapy research and cell analysis business with the flow cytometry expertise of Propel Labs, engineering strength, and R&D abilities.
Market Segments covered in the Report:
By Product Type
By End-Use
By Cells Type
By Technique
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures